

## Kalydeco® (ivacaftor) - Expanded indication and new dosage strengths

- On May 3, 2023, <u>Vertex Pharmaceuticals</u> announced the <u>FDA approval</u> of <u>Kalydeco (ivacaftor)</u>, for the treatment of cystic fibrosis (CF) in patients age 1 month and older who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (*CFTR*) gene that is responsive to ivacaftor potentiation based on clinical and/or *in vitro* assay data.
  - Kalydeco was previously approved for this indication in patients age 4 months and older.
  - If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use.
- In addition to the expanded indication, the FDA approved two new dosage strengths (5.8 mg and 13.4 mg) of Kalydeco oral granules.
  - The oral granules are also available in a 25 mg, 50 mg, and 75 mg strength and Kalydeco is also available as a 150 mg oral tablet.
- The effectiveness of Kalydeco in patients aged 1 month to less than 24 months was extrapolated from patients 6 years of age and older with support from population pharmacokinetic analyses showing that the exposure of ivacaftor in pediatric patients 1 month to less than 24 months of age is within the range of exposure in adults and pediatric patients 6 years of age and older. The safety of Kalydeco for the expanded indication was derived from a cohort of 7 patients aged 1 month to less than 4 months (mean age 1.9 months at baseline).
- The recommended dosage of Kalydeco (oral granules) for pediatric patients age 1 month to less than 2 months, with a body weight 3 kg or greater, is one packet (containing 5.8 mg ivacaftor) every 12 hours. In pediatric patients age 2 month to less than 4 months, with a body weight 3 kg or greater, the recommended dosage is one packet (containing 13.4 mg ivacaftor) every 12 hours.
  - Refer to the Kalydeco drug label for dosing for patients age 4 months and older.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.